Biomod/2011/Caltech/DeoxyriboNucleicAwesome/Project: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
(Filling in sequence design, simulation sections and links) |
||
Line 1: | Line 1: | ||
{{Template:DeoxyriboNucleicAwesomeHeader}} | {{Template:DeoxyriboNucleicAwesomeHeader}} | ||
==Sequence Design== | ==Sequence Design== | ||
:''Main article: [[Biomod/2011/Caltech/DeoxyriboNucleicAwesome/Sequence Design|Sequence Design]]'' | |||
With our overall design in mind, we must design DNA sequences, down to the base level, which undergo the interactions that we desire, without forming secondary structures and binding in unintended ways. We approach this through a combination of pre-generated noninteracting sequences, and trial-and-error design using NUPACK simulation software. | |||
==Simulation of Expected Results== | |||
:''Main article: [[Biomod/2011/Caltech/DeoxyriboNucleicAwesome/Simulation|Simulation]]'' | |||
Before undertaking our experiments, it's desirable to have an idea what our results our going to look like, particularly in the case of random walking, which we intend to investigate rather thoroughly. To do this, we use a stochastic simulation, written in MATLAB. | |||
{{Template:DeoxyriboNucleicAwesomeFooter}} | {{Template:DeoxyriboNucleicAwesomeFooter}} |
Revision as of 11:24, 21 June 2011
Thursday, April 25, 2024
|
Sequence Design
With our overall design in mind, we must design DNA sequences, down to the base level, which undergo the interactions that we desire, without forming secondary structures and binding in unintended ways. We approach this through a combination of pre-generated noninteracting sequences, and trial-and-error design using NUPACK simulation software. Simulation of Expected Results
Before undertaking our experiments, it's desirable to have an idea what our results our going to look like, particularly in the case of random walking, which we intend to investigate rather thoroughly. To do this, we use a stochastic simulation, written in MATLAB.
|